




Exyte Group

Financial Statement 3M/2023 - Summary

May 23, 2023



Key Figures 3M/2023*



* All figures are unaudited.

¹ Change year-on-year.

² Full-time equivalents as of March 31, 2023.

Figures at a Glance 3M/2023




Key Figures Exyte Group

in € million


	Jan. 1 - Mar. 31, 2023	Jan. 1 - Mar. 31, 2022	Growth
Order intake	2,396	2,630	-8.9%
Sales	2,028	1,518	33.6%
Gross profit	160	138	15.9%
Gross profit margin in %	7.9	9.1	-1.2PP
EBIT	109	91	19.8%
EBIT margin in %	5.4	6.0	-0.6PP
Adjusted EBIT	113	95	18.9%
Adjusted EBIT margin in %	5.6	6.3	-0.7PP
Adjusted EBITDA	125	105	19.0%
Adjusted EBITDA margin in %	6.2	6.9	-0.7PP
Group net profit	100	82	22.0%
Group net profit margin in %	4.9	5.4	-0.5PP
No. of Employees (full-time equivalents at the end of period)	9,480	7,920	19.7%
Cash flow from operating activities	148	449	-
Cash flow from investing activities	-6	-5	-
Free cash flow	142	443	-
Order backlog (at the end of period)	7,119	7,869	-9.5%

Key Financials 3M/2023 I



- Strong order intake driven by high demand from the clients, particularly in semiconductor industry.
 - Substantial order backlog of 7,119 Mio. € ensures future profitable sales growth.
-
- Significant increase of sales due to flawless execution of large Advanced Technology Facilities (ATF) projects worldwide.
 - Substantial sales development and growth also coming from Biopharma and Life Sciences (BLS), Data Centers (DTC) as well as Technology & Services (T&S).

Key Financials 3M/2023 II



- Adjusted EBIT of 3M/2023 outperformed 3M/2022 following sales growth.
- Along with the growth of adjusted EBIT, adjusted EBITDA improved to 125 Mio. € in the first three months of 2023.

1) For explanation of adjusted EBIT, please see "Earnings Performance."


Order Intake by Region 3M/2023

Order intake by region¹

in € million

	3M/2023	3M/2022
APAC	334	1,777
EMEA	1,616	439
AMER	177	218
T&S	312	293

in % (previous year)



¹ Before consolidation of the regions.

High order intake in EMEA

- Constant shift of business demand from APAC to EMEA and US in ATF segment as a result of support policies of EU and US.
- Award of a project with significant volume (over 1 billion €) occurred in EMEA in current year vs. in APAC in previous year.
- T&S with strong contribution to the Group order intake.

Order Intake by Business Segment 3M/2023


Continuous positive development in ATF and BLS

- ATF business segment remains largest segment with a share of almost 89% of the Group order intake. Significant projects have been awarded in Germany and the US.
- Order intake of BLS business segment increased by over 65% compared to previous year.
- Order intake of DTC developed as expected due to less project awards in the first quarter of 2023 compared to 3M/2022. Strong quarters expected until year-end.

Order intake by business segment

in € million	3M/2023	3M/2022
ATF	2,129	2,344
BLS	140	83
DTC	45	187
RSB	82	15

in % (previous year)




Sales by Region 3M/2023

Sales by region¹

in € million

	3M/2023	3M/2022
APAC	1,085	780
EMEA	564	511
AMER	247	94
T&S	207	173

in % (previous year)



¹ Before consolidation of the regions.

Excellent performances in all regions

- 3M/2023 sales in all regions incl. T&S ahead of comparable period 2022.
- APAC's performance remains on a high level due to large projects in execution in Asia.
- US more than doubled sales compared to 3M/2022.
- T&S successfully continuing their growth initiatives.

Sales by Business Segment 3M/2023

ATF continues to be the main growth driver


- 3M/2023 Sales in all business segments above the levels of 3M/2022.
- Due to the execution of large-scale semiconductor projects in all regions, the ATF business segment continues to grow on a year-on-year basis.
- BLS business segment increased sales due to major projects in Germany, Malaysia, and Singapore.
- Sales increase in DTC business segment mainly driven by multiple projects in Denmark, Israel and Malaysia.

Sales by business segment

in € million

	3M/2023	3M/2022
ATF	1,780	1,325
BLS	140	126
DTC	93	51
RSB	15	16

in % (previous year)



Earnings Performance 3M/2023



Adjusted EBIT¹

in € million

	3M/2023	3M/2022
Reported EBIT	109.4	90.9
Adjustments	3.7	4.2
of which due to restructuring measures	0.1	1.9
of which related to depreciation of PPAs	1.9	1.6
of which other adjustments	1.7	0.7
Adjusted EBIT¹	113.1	95.1

Profitability improved

- Adjusted EBIT¹ (adjusted earnings before interest and taxes) increased considerably compared to 3M/2022.
- The adjusted EBIT margin decreased to 5.6% in 3M/2023 (0.7PP lower than 3M/2022) due to project mix.

1) Adjusted EBIT is defined as the result from operating activities (earnings before interest and tax; EBIT) adjusted for income or expenses deriving from non-recurring effects. EBIT adjustments result from income or expenses related to the Exyte Group's reorganization, costs of restructuring measures, costs incurred due to site closures and relocations, effects on earnings from purchase price allocations or other income or expenses that are non-recurring in nature or are incurred outside the normal course of business, as well as COVID 19-related effects. Adjusted EBIT is used to determine profitability excluding non-recurring positive or negative effects, thus ensuring comparability between different reporting periods.

Outlook Financial Year 2023



We anticipate the global economy to continue to recover. However, we still assume that fiscal policies and geopolitical tensions will continue to have a negative impact on the overall economic development in 2023.

Due to the unchanged positive surrounding conditions in the industry sectors in which we are active, we expect the 2023 order intake to be at a comparable level to the previous year. Based on the high order backlog at the end of 2022 and planned new orders, we expect a further increase in sales to around €8.0 billion in 2023. In line with sales, we also expect an absolute increase in adjusted EBIT for 2023.

This presentation contains forward-looking statements that reflect our current view about future business and financial performance as well as future events or developments. Forward-looking statements are characterized by the use of words such as “expect,” “intend,” “plan,” “predict,” “assume,” “believe,” “estimate,” “anticipate,” and similar expressions. These statements are based on current expectations and assumptions made by the executive management of Exyte Group and are subject to many risks and uncertainties which are mainly beyond Exyte’s control. Should any of these risks or uncertainties materialize or any expectations or assumptions prove to be incorrect, the actual future results may be materially different from those described explicitly or implicitly in the relevant forward-looking statement. Therefore, Exyte does not guarantee any of these forward-looking statements and neither intends nor assumes any obligation to update or revise those in case of developments which differ from those anticipated.

Exyte Group accepts no liability for the accuracy and completeness of information provided in this presentation.



Exyte
René Ziegler
Corporate Communications & Investor Relations
Löwentorbogen 9b
70376 Stuttgart
Germany

T +49 711 8804 4606

ir@exyte.net